Iovance highlights TIL therapy platform at ESMO Congress
Iovance highlighted its tumor-infiltrating lymphocyte (TIL) cell therapy platform across solid tumors at the 2026 European Society for Medical Oncology Congress.
Story updates
11:08:22 AM UTC
SquawkNews
Iovance Advances TIL Cell Therapy into a New Chapter in Solid Tumor TreatmentTwo Oral Presentations to Showcase Deep, Durable Responses with TIL Cell Therapy in Frontline Melanoma and Previously Treated Soft Tissue SarcomasPHILADELPHIA, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc…